P3781
Pazopanib for the treatment of metastatic renal cell carcinomaPazopanib in the treatment of soft tissue sarcomaSafety and tolerability of pazopanib in the treatment of renal cell carcinomaPhase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.Reversible posterior leukoencephalopathy syndrome induced by pazopanib.Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Concise drug review: pazopanib and axitinib.Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.Pazopanib for the treatment of breast cancer.A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.Pazopanib: in advanced soft tissue sarcoma.An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.Self-assembled phenylalanine-α,β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor.Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.[Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib RespondersThe challenge of finding new therapeutic avenues in soft tissue sarcomasOveractive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial SarcomaReal-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern CaliforniaAssessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective studyPazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysisA phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumorsLiquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma
P921
Q21100975-4383F70F-0683-43B7-86B1-8C19950BF35FQ21108624-C2693F1D-CA19-43DB-BC63-53A8D7FAEC46Q21115605-6D11E539-72F9-4873-921A-D4BD81F14F7EQ21118353-B9F8961E-9CA6-4752-A646-6AB88A8743E0Q21172390-44DBCFE8-2268-4B66-BB39-7170C834AC23Q5446453-51B88F08-5541-49FE-82F3-10DE70F40A60Q909409-7A7D03DB-E64C-492B-A95E-BCC32A6E00CC
P129
Q1164529-8AC4F884-44D5-469C-A700-235D2E959046Q1164529-97060209-6702-400B-9DB0-3176D9C9C13BQ1495661-7DB74AA3-D798-4DDA-8B9F-E464C1EE3192Q18553680-36613CE1-BA41-4F74-B738-FA0308E6E65AQ18556340-3F5C07D8-8AD3-4437-9E2E-0125C1FA0621Q18556721-0CD5885C-AAC1-4F7B-8CA2-BB8D5298A7A7Q1989240-9A915714-B905-4652-A9EC-AAC3B835B09BQ2619315-36F998E8-F8A0-4E05-B417-E4EFD7DCAF75Q3242950-B75426D5-3AA1-4F47-811A-3A284C64DC68Q56014392-70A26027-CD18-488F-9157-FF4A73967E4EQ5965479-157AB8AF-854F-4FA2-AD23-FBF5C039250B
P2176
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Pasopaniib
@et
Pazopanib
@de
Pazopanib
@en-ca
Pazopanib
@en-gb
Pazopanib
@es
Pazopanib
@nl
Pazopanib
@sh
Pazopanib
@sr
Pazopanibas
@lt
Pazopanibe
@pt-br
type
label
Pasopaniib
@et
Pazopanib
@de
Pazopanib
@en-ca
Pazopanib
@en-gb
Pazopanib
@es
Pazopanib
@nl
Pazopanib
@sh
Pazopanib
@sr
Pazopanibas
@lt
Pazopanibe
@pt-br
altLabel
GW 78603
@en
GW 786034
@en
GW786034
@en
PZP034
@en
Pazopanib
@pt
Votrient
@pt
indazolylpyrimidine 13
@en
prefLabel
Pasopaniib
@et
Pazopanib
@de
Pazopanib
@en-ca
Pazopanib
@en-gb
Pazopanib
@es
Pazopanib
@nl
Pazopanib
@sh
Pazopanib
@sr
Pazopanibas
@lt
Pazopanibe
@pt-br